Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal

ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently has no effective therapy. To date, clinically applicable targeted cancer therapy based on ARID1A mutational status...

Descripción completa

Detalles Bibliográficos
Autores principales: Biter, Benjamin G., Aird, Katherine M., Garipov, Azat, Li, Hua, Amatangelo, Michael, Kossenkov, Andrew V., Schultz, David C., Liu, Qin, Shih, Ie-Ming, Conejo-Garcia, Jose R., Speicher, David W., Zhang, Rugang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352133/
https://www.ncbi.nlm.nih.gov/pubmed/25686104
http://dx.doi.org/10.1038/nm.3799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352133/
https://www.ncbi.nlm.nih.gov/pubmed/25686104
http://dx.doi.org/10.1038/nm.3799

Ejemplares similares